Semaglutide in Heart Failure With Preserved Ejection Fraction and Obesity
Compared with placebo in the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg reduced symptoms and physical limitations, improved exercise function, and produced weight loss, investigators report.